Reported Earnings • Apr 25
First quarter 2026 earnings released: EPS: CN¥0.017 (vs CN¥0.016 loss in 1Q 2025) First quarter 2026 results: EPS: CN¥0.017 (up from CN¥0.016 loss in 1Q 2025). Revenue: CN¥118.6m (up 381% from 1Q 2025). Net income: CN¥4.16m (up CN¥9.12m from 1Q 2025). Profit margin: 3.5% (up from net loss in 1Q 2025). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has increased by 17% per year, which means it is well ahead of earnings. Announcement • Apr 25
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd., Annual General Meeting, May 22, 2026 Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd., Annual General Meeting, May 22, 2026, at 14:00 China Standard Time. Location: No. 569, Beijing North Road, Changji, Xinjiang China Announcement • Mar 31
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. to Report Q1, 2026 Results on Apr 25, 2026 Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. announced that they will report Q1, 2026 results on Apr 25, 2026 New Risk • Mar 30
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 29% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.7% average weekly change). New Risk • Jan 28
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 7.4% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CN¥44m free cash flow). Earnings have declined by 29% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (7.4% average weekly change). Announcement • Dec 31
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. to Report Fiscal Year 2025 Results on Apr 25, 2026 Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. announced that they will report fiscal year 2025 results on Apr 25, 2026 Board Change • Nov 01
High number of new directors There are 8 new directors who have joined the board in the last 3 years. Non Independent Director Yun Yang was the last director to join the board, commencing their role in 2025. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model. New Risk • Oct 25
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -CN¥44m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CN¥44m free cash flow). Earnings have declined by 29% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.4% average weekly change). Announcement • Oct 14
Xinjiang Tianshan Animal Husbandry Bio-Engineering Co., Ltd. Approves Board Elections Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. held its 2nd Extraordinary General Meeting of 2025 on 10 October 2025, approved the Election and nomination of non-independent directors: Chen Mingyi, non-independent director; Yang Yun, non-independent director; Guo Yunchuan, non-independent director; Chen Jie, non-independent director. Election and nomination of independent directors: Liu Zongliu, independent director; Chen Jidong, independent director; Li Kaihui, independent director. Announcement • Sep 30
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. to Report Q3, 2025 Results on Oct 25, 2025 Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. announced that they will report Q3, 2025 results on Oct 25, 2025 Reported Earnings • Aug 27
Second quarter 2025 earnings released: CN¥0.009 loss per share (vs CN¥0.066 loss in 2Q 2024) Second quarter 2025 results: CN¥0.009 loss per share (improved from CN¥0.066 loss in 2Q 2024). Revenue: CN¥17.0m (down 43% from 2Q 2024). Net loss: CN¥2.84m (loss narrowed 86% from 2Q 2024). Over the last 3 years on average, earnings per share has fallen by 27% per year but the company’s share price has increased by 3% per year, which means it is well ahead of earnings. Announcement • Jul 02
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. to Report First Half, 2025 Results on Aug 27, 2025 Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. announced that they will report first half, 2025 results on Aug 27, 2025 New Risk • Jun 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 16% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (8.3% average weekly change). New Risk • Jun 07
New major risk - Revenue and earnings growth Earnings have declined by 16% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. This is currently the only risk that has been identified for the company. New Risk • May 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. This is currently the only risk that has been identified for the company. Announcement • Apr 29
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd., Annual General Meeting, May 22, 2025 Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd., Annual General Meeting, May 22, 2025, at 15:00 China Standard Time. Announcement • Mar 31
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. to Report Q1, 2025 Results on Apr 29, 2025 Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. announced that they will report Q1, 2025 results on Apr 29, 2025 New Risk • Feb 19
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Chinese stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company. Announcement • Dec 31
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. to Report Fiscal Year 2024 Results on Apr 18, 2025 Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. announced that they will report fiscal year 2024 results on Apr 18, 2025 Reported Earnings • Oct 30
Third quarter 2024 earnings released: CN¥0.044 loss per share (vs CN¥0 in 3Q 2023) Third quarter 2024 results: CN¥0.044 loss per share (further deteriorated from CN¥0 in 3Q 2023). Revenue: CN¥59.0m (down 10.0% from 3Q 2023). Net loss: CN¥13.8m (down CN¥13.9m from profit in 3Q 2023). Over the last 3 years on average, earnings per share has fallen by 13% per year whereas the company’s share price has fallen by 11% per year. Announcement • Sep 30
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. to Report Q3, 2024 Results on Oct 24, 2024 Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. announced that they will report Q3, 2024 results on Oct 24, 2024 Reported Earnings • Aug 28
Second quarter 2024 earnings released: CN¥0.066 loss per share (vs CN¥0.029 loss in 2Q 2023) Second quarter 2024 results: CN¥0.066 loss per share (further deteriorated from CN¥0.029 loss in 2Q 2023). Revenue: CN¥29.8m (up 23% from 2Q 2023). Net loss: CN¥20.6m (loss widened 126% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 18% per year whereas the company’s share price has fallen by 16% per year. Announcement • Jun 29
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. to Report First Half, 2024 Results on Aug 28, 2024 Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. announced that they will report first half, 2024 results on Aug 28, 2024 Reported Earnings • Apr 24
First quarter 2024 earnings released: CN¥0.023 loss per share (vs CN¥0.013 loss in 1Q 2023) First quarter 2024 results: CN¥0.023 loss per share (further deteriorated from CN¥0.013 loss in 1Q 2023). Revenue: CN¥17.5m (down 24% from 1Q 2023). Net loss: CN¥7.21m (loss widened 80% from 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 15% per year, which means it has not declined as severely as earnings. Announcement • Dec 30
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024 Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. announced that they will report fiscal year 2023 results on Mar 30, 2024 Reported Earnings • Oct 25
Third quarter 2023 earnings released: EPS: CN¥0 (vs CN¥0.052 loss in 3Q 2022) Third quarter 2023 results: EPS: CN¥0 (improved from CN¥0.052 loss in 3Q 2022). Revenue: CN¥65.5m (up 276% from 3Q 2022). Net income: CN¥99.5k (up CN¥16.4m from 3Q 2022). Profit margin: 0.2% (up from net loss in 3Q 2022). Over the last 3 years on average, earnings per share has fallen by 35% per year but the company’s share price has only fallen by 13% per year, which means it has not declined as severely as earnings. Reported Earnings • Aug 26
Second quarter 2023 earnings released: CN¥0.029 loss per share (vs CN¥0.023 loss in 2Q 2022) Second quarter 2023 results: CN¥0.029 loss per share (further deteriorated from CN¥0.023 loss in 2Q 2022). Revenue: CN¥24.2m (up 47% from 2Q 2022). Net loss: CN¥9.12m (loss widened 25% from 2Q 2022). Over the last 3 years on average, earnings per share has fallen by 20% per year but the company’s share price has fallen by 29% per year, which means it is performing significantly worse than earnings. Reported Earnings • Apr 26
First quarter 2023 earnings released: CN¥0.013 loss per share (vs CN¥0.015 loss in 1Q 2022) First quarter 2023 results: CN¥0.013 loss per share (improved from CN¥0.015 loss in 1Q 2022). Revenue: CN¥23.2m (up 85% from 1Q 2022). Net loss: CN¥4.02m (loss narrowed 15% from 1Q 2022). Over the last 3 years on average, earnings per share has increased by 2% per year whereas the company’s share price has increased by 6% per year. Board Change • Nov 16
High number of new and inexperienced directors There are 11 new directors who have joined the board in the last 3 years. The company's board is composed of: 11 new directors. No experienced directors. No highly experienced directors. Supervisor Jun Zhang is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Oct 25
Third quarter 2022 earnings released: CN¥0.052 loss per share (vs CN¥0.036 loss in 3Q 2021) Third quarter 2022 results: CN¥0.052 loss per share (further deteriorated from CN¥0.036 loss in 3Q 2021). Revenue: CN¥17.4m (down 14% from 3Q 2021). Net loss: CN¥16.3m (loss widened 42% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 32% per year but the company’s share price has only increased by 1% per year, which means it is significantly lagging earnings growth. Reported Earnings • Aug 31
Second quarter 2022 earnings released: CN¥0.023 loss per share (vs CN¥0.026 loss in 2Q 2021) Second quarter 2022 results: CN¥0.023 loss per share (up from CN¥0.026 loss in 2Q 2021). Revenue: CN¥16.5m (down 45% from 2Q 2021). Net loss: CN¥7.31m (loss narrowed 10% from 2Q 2021). Over the last 3 years on average, earnings per share has increased by 57% per year but the company’s share price has only increased by 12% per year, which means it is significantly lagging earnings growth. Reported Earnings • Apr 28
First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind First quarter 2022 results: CN¥0.015 loss per share (down from CN¥0.007 loss in 1Q 2021). Revenue: CN¥12.5m (up 18% from 1Q 2021). Net loss: CN¥4.70m (loss widened 117% from 1Q 2021). Revenue exceeded analyst estimates by 39%. Earnings per share (EPS) missed analyst estimates. Over the last 3 years on average, earnings per share has increased by 149% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings. Board Change • Apr 27
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 2 experienced directors. 1 highly experienced director. Employee Supervisor Lijun Wang is the most experienced director on the board, commencing their role in 2009. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Jan 20
High number of new and inexperienced directors There are 9 new directors who have joined the board in the last 3 years. The company's board is composed of: 9 new directors. 2 experienced directors. 1 highly experienced director. Employee Supervisor Lijun Wang is the most experienced director on the board, commencing their role in 2009. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Board Change • Oct 31
High number of new directors Chairman of the Board Bo Peng was the last director to join the board, commencing their role in 2019. Reported Earnings • Aug 30
Second quarter 2021 earnings released: CN¥0.026 loss per share (vs CN¥0.009 loss in 2Q 2020) The company reported a poor second quarter result with increased losses, weaker revenues and weaker control over costs. Second quarter 2021 results: Revenue: CN¥30.0m (down 58% from 2Q 2020). Net loss: CN¥8.16m (loss widened 191% from 2Q 2020). Over the last 3 years on average, earnings per share has increased by 126% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings. Reported Earnings • Apr 28
First quarter 2021 earnings released: CN¥0.007 loss per share (vs CN¥0.015 loss in 1Q 2020) The company reported a soft first quarter result with weaker revenues and control over costs, although losses reduced. First quarter 2021 results: Revenue: CN¥10.6m (down 73% from 1Q 2020). Net loss: CN¥2.16m (loss narrowed 55% from 1Q 2020). Over the last 3 years on average, earnings per share has increased by 99% per year but the company’s share price has only increased by 7% per year, which means it is significantly lagging earnings growth. Is New 90 Day High Low • Jan 27
New 90-day low: CN¥18.43 The company is down 22% from its price of CN¥23.76 on 29 October 2020. The Chinese market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 5.0% over the same period. Reported Earnings • Oct 28
Third quarter earnings released Over the last 12 months the company has reported total losses of CN¥36.2m, with losses narrowing by 29% from the prior year. Total revenue was CN¥282.4m over the last 12 months, up 141% from the prior year. Announcement • Oct 20
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020 Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. announced that they will report Q3, 2020 results on Oct 28, 2020 Announcement • Aug 13
Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020 Xinjiang Tianshan Animal Husbandry Bio-engineering Co., Ltd. announced that they will report first half, 2020 results on Aug 28, 2020